» Articles » PMID: 8574164

P53 Mutations, C-myc and Bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 1995 Sep 1
PMID 8574164
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Fourteen Non-Hodgkin's lymphoma cell lines were generated and assessed for the presence of structural p53, c-myc and bcl-2 gene changes. Single or multiple changes were observed in 11 of the lines. Alterations of the p53 gene were most frequent and documented for 10 lines by immunoprecipitation using the antibodies PAb 240 and PAb 1801, sequencing studies and Southern blot analysis. A detailed study was performed in one of the cell lines (OCI-Ly 4) for which material of the original tumor sample was available. Two point mutations identified by sequencing cDNA derived from the cell line were also present in the original tumor specimen. In contrast, DNA prepared from fibroblasts of the same patient did not show the mutations. Six of the 14 lines demonstrated c-myc rearrangements, while bcl-2 changes were observed in 4. The presence of c-myc was associated with shorter survival of this group of patients with aggressive disease. None of the other changes present as single or composite alterations were correlated with clinical outcome measures.

Citing Articles

Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma.

Schnorenberg M, Hawley K, Thomas-Toth A, Watkins E, Tian Y, Ting J ACS Nano. 2023; 17(23):23374-23390.

PMID: 37688780 PMC: 10722602. DOI: 10.1021/acsnano.3c04112.


Identification of two unannotated miRNAs in classic Hodgkin lymphoma cell lines.

Ustaszewski A, Paczkowska J, Janiszewska J, Bernhart S, Bein J, Russinol N PLoS One. 2023; 18(3):e0283186.

PMID: 36961799 PMC: 10038261. DOI: 10.1371/journal.pone.0283186.


In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines.

Dharanipragada P, Parekh N Cells. 2023; 12(4).

PMID: 36831263 PMC: 9954129. DOI: 10.3390/cells12040596.


Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.

Kroonen J, de Graaf I, Kumar S, Remst D, Wouters A, Heemskerk M Leukemia. 2023; 37(4):864-876.

PMID: 36792656 PMC: 10079526. DOI: 10.1038/s41375-023-01838-8.


miR-181c regulates MCL1 and cell survival in GATA2 deficient cells.

Wang W, Chen R, Droll S, Barber E, Saleh L, Corrigan-Cummins M J Leukoc Biol. 2021; 111(4):805-816.

PMID: 34270823 PMC: 10506419. DOI: 10.1002/JLB.2A1220-824R.